GoodRx Holdings, Inc. Class A Common Stock (GDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
Novo Nordisk expands access to Ozempic, Wegovy through GoodRx and other platforms
Novo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the therapy for those who do not have insurance coverage. Patients can pay $499 in cash per month through the drug's website, Novo Nordisk's patient assistance program, the company's direct-to-consumer online pharmacy and via drug savings platform GoodRx.
GoodRx Holdings, Inc. (GDRX) Q2 2025 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Christopher A. McGinnis - CFO & Treasurer Wendy Barnes - President, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R.
Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics
The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.08 per share a year ago.
GDRX vs. HQY: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
GoodRx: A One Big Beautiful Bill Act Beneficiary
GoodRx connects uninsured and underinsured consumers with prescription discounts, acting as a broker between consumers, PBMs, and pharmacies. Recent OBBBA legislation will significantly cut Medicaid spending, leaving millions more Americans uninsured or underinsured over the next decade. GoodRx stands to benefit as its platform becomes increasingly relevant for the growing population losing Medicaid coverage and seeking affordable prescriptions.
GoodRx: Stabilizing Revenue Amid Healthy Profit Gains
I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma partnerships, and robust EBITDA margins support the investment thesis for a rebound. Despite risks like Rite Aid's bankruptcy and flat consumer growth, GoodRx's direct pharma channel is growing double digits and offsetting headwinds.
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value investors?
GoodRx Holdings, Inc. (GDRX) Q1 2025 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Aubrey Reynolds – Director-Investor Relations Wendy Barnes – President and Chief Executive Officer Chris McGinnis – Chief Financial Officer Conference Call Participants Lisa Gill – JPMorgan John Ransom – RJF Charles Rhyee – TD Cowen Jailendra Singh – Truist Securities Craig Hettenbach – Morgan Stanley George Hill – Deutsche Bank Steven Valiquette – Mizuho Securities Allen Lutz – Bank of America Michael Cherny – Leerink Partners Daniel Grosslight – Citi Operator Ladies and gentlemen, thank you for standing by and welcome to the GoodRx First Quarter 2025 Earnings Call. As a reminder, today's conference is being recorded.
Is GoodRx (GDRX) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.
